Serum Cystatin C as a predictor of acute kidney injury in neonates: a meta-analysis
J. pediatr. (Rio J.)
; 98(3): 230-240, May-June 2022. tab, graf
Article
in En
|
LILACS-Express
| LILACS
| ID: biblio-1386090
Responsible library:
BR1.1
ABSTRACT
Abstract Objective:
The objective of this meta-analysis is to evaluate the diagnostic value of serum Cystatin C in acute kidney injury (AKI) in neonates Sources PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), and WanFang Database were searched to retrieve the literature related to the diagnostic value of Cystatin C for neonatal AKI from inception to May 10, 2021. Subsequently, the quality of included studies was determined using the QUADAS-2 tool. Stata 15.0 statistical software was used to calculate the combined sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Additionally, meta-regression analysis and subgroup analysis contributed to explore the sources of heterogeneity Summary of thefindings:
Twelve articles were included. The pooled sensitivity was 0.84 (95%CI 0.74-0.91), the pooled specificity was 0.81 (95%CI 0.75-0.86), the pooled PLR was 4.39 (95%CI 3.23-5.97), the pooled NLR was 0.19 (95%CI 0.11-0.34), and the DOR was 22.58 (95%CI 10.44-48.83). The area under the receiver operating characteristic curve (AUC) was 0.88 (95%CI 0.85-0.90). No significant publication bias was identified (p > 0.05).
Full text:
1
Index:
LILACS
Type of study:
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Language:
En
Journal:
J. pediatr. (Rio J.)
Journal subject:
PEDIATRIA
Year:
2022
Type:
Article